This Week in Lancet Oncology

Premium

In Lancet Oncology this week, researchers in the US and Belgium report the results of a phase II trial of ipilimumab for the treatment of patients with advanced melanoma that has metastasized to the brain. The team assigned 72 melanoma patients with brain metastases — 51 of whom were neurologically asymptomatic and were not receiving corticosteroid treatment and 21 of whom were symptomatic and on a stable dose of corticosteroids — to receive ipilimumab therapy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.